Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program.

被引：0
|
作者：
Philip, Philip Agop
Smaglo, Brandon George
El-Rayes, Bassel F.
Lesuisse, Christian
Makris, Lukas
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[3] Emory Univ, Winship Canc Inst, Dept Med Oncol, Atlanta, GA 30322 USA
[4] Taiho Oncol Inc, Princeton, NJ USA
[5] Stathmi Inc, New Hope, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15039
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
    Koper, Agnieszka
    Wilenski, Slawomir
    Sledzinska, Paulina
    Bebyn, Marek
    Koper, Krzysztof
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10867 - 10877
  • [22] Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
    Ozet, Ahmet
    Dane, Faysal
    Aykan, Nuri Faruk
    Yalcin, Suayib
    Evrensel, Turkkan
    Ozkan, Metin
    Karabulut, Bulent
    Ormeci, Merve Nur
    Atasev, Ozan
    Vidot, Loick
    Cicin, Irfan
    FUTURE ONCOLOGY, 2022, 18 (29) : 3267 - 3276
  • [23] Trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer treatment
    Michel, Patryk S.
    Jankowski, Marek
    Sigorski, Dawid
    Kubiatowski, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (06):
  • [24] A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer
    Zou, Jiayun
    Wang, Yuanyuan
    Xu, Jiayu
    Li, Jinna
    Wang, Tianzhuo
    Zhang, Ying
    Bai, Yibo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [25] Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
    Malik, Mateusz
    Michalak, Maciej
    Radecka, Barbara
    Gelej, Marek
    Jackowska, Aleksandra
    Filipczyk-Cisarz, Emilia
    Hetman, Katarzyna
    Foszczynska-Kloda, Malgorzata
    Kania-Zembaczynska, Beata
    Manka, Danuta
    Orlikowska, Marlena
    Rogowska-Dros, Hanna
    Bodnar, Lubomir
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [26] Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
    Agnieszka Koper
    Sławomir Wileński
    Paulina Śledzińska
    Marek Bebyn
    Krzysztof Koper
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 10867 - 10877
  • [27] Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer
    Stefan Kasper
    Jens Kisro
    Martin Fuchs
    Christian Müller
    Armin Schulz-Abelius
    Meinolf Karthaus
    Mohammad-Reza Rafiyan
    Alexander Stein
    BMC Cancer, 18
  • [28] Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer
    Kasper, Stefan
    Kisro, Jens
    Fuchs, Martin
    Mueller, Christian
    Schulz-Abelius, Armin
    Karthaus, Meinolf
    Rafiyan, Mohammad-Reza
    Stein, Alexander
    BMC CANCER, 2018, 18
  • [29] Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe M.
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik P.
    Benhadji, Karim A.
    Amellal, Nadia
    Leger, Catherine
    Vidot, Loick
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (18): : 1657 - 1667
  • [30] Trifluridine/tipiracil in metastatic colorectal cancer: a guide to its use
    Lyseng-Williamson K.A.
    Burness C.B.
    Duggan S.T.
    Drugs & Therapy Perspectives, 2017, 33 (3) : 110 - 118
12345